Home > Publications database > Molecular subtypes of intrahepatic cholangiocarcinoma. |
Journal Article (Review Article) | DKFZ-2025-00379 |
; ; ; ;
2025
Elsevier Science
Amsterdam [u.a.]
This record in other databases:
Please use a persistent id in citations: doi:10.1016/j.molmed.2025.01.008
Abstract: Intrahepatic cholangiocarcinoma (iCCA) presents in two clinically distinct subtypes: large duct (LD-iCCA) and small duct (SD-iCCA). These subtypes exhibit significant molecular, genetic, and histopathological differences that impact patient prognosis and treatment responsiveness. This review advocates for a subtype-specific approach to iCCA research and clinical management, including tailored therapeutic strategies that consider distinct genetic profiles and tumor microenvironments. Current therapeutic approaches hold promise, yet efficacy varies by subtype. Additionally, subtype-specific molecular diagnostics, including DNA methylation-based classifiers and transcriptomic sequencing, have shown potential in refining iCCA subclassification, thereby guiding precision medicine efforts. This article outlines existing clinical trials, key research trajectories, and future directions for developing more effective subtype-adapted therapies for iCCA.
Keyword(s): clinical trial ; intrahepatic cholangiocarcinoma ; molecular targeted therapy ; mutation ; survival ; translational research
![]() |
The record appears in these collections: |